Introduction: Consumption coagulopathy or disseminated intravascular coagulation (DIC) corresponds to uncontrolled activation of coagulation in an anatomically intact vascular network leading to fibrin deposition in the vasculature, organ dysfunction, and consumption of clotting factors and platelets, and life-threatening hemorrhage. This is an acute and severe pathological situation with a very unpleasant prognosis providing very high mortality. Materials and methods: The study was conducted on a complicated case of chronic myeloid leukemia (CML) with disseminated intravascular coagulation (DIC). Observation: We report a case of a 75-year-old patient followed for type II diabetes and dyslipidemia under treatment who presented with generalized fatigue and a history of left hypochondrium discomfort. The abdominal examination revealed a splenomegaly (5 cm from the cost overhang). The rest of the clinical examination was without peculiarity. On investigation, he was found to have a major hyperleukocytosis at 111.

Original Research ArticleThe production of autoantibodies after a hematopoietic stem cell allograft is a fact observed in hematology and often observed during graft versus host disease (GVHD) following an immune disturbance, however studies have shown the possibility of transferring B cells memory from a donor to the recipient and be responsible for autoimmune manifestations similar to that observed in the donor. We present here an extremely rare case of a manifestation of an isolated anti-phospholipid syndrome, 7 years after allograft in a patient whose donor is always asymptomatic. The appearance of autoantibodies was preceded by the appearance of chronic GVHD and the patient posed a management problem in the face of her persistent thrombocytopenia. The distinction between the manifestation of chronic GVHD and adoptive immunity is necessary due to the prognostic and therapeutic differences between these two entities.

No abstract

The occurrence of acute leukemia after treated multiple myeloma has long raised concerns and has been the subject of several studies which have been based mainly on the link with treatments, mainly those using alkylating agents, but they remain limited due to the small number of patients, insufficient follow-up and limits for detecting second malignant tumors. Although the underlying biological mechanisms of AML after multiple myeloma are unknown, treatment-related factors are believed to be responsible. Recently, an excessive risk of acute leukemia has been found among 5652 patients with monoclonal gammopathy of undetermined significance IgG / IgA (but not IgM) supporting the role of disease-related factors. In addition, there is evidence to suggest that genetic polymorphisms may contribute to a person's susceptibility to future cancers, while the potential influence of environmental and behavioral factors remains poorly understood. This article discusses, through the observation of our patient, the current knowledge concerning malignant tumors after multiple myeloma and gives future directions for efforts to characterize the underlying biological mechanisms, with the aim of increasing survival and minimize the risk of new malignancies.